Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8615-8629

  Zech, Gernot ^a   Hessler, Gerhard ^a   Evers, Andreas ^a   Weiss, Tilo ^a   Florian, Peter ^a   Just, Melitta ^a   Czech, Jörg ^a   Czechtizky, Werngard ^a   Görlitzer, Jochen ^a   Ruf, Sven ^a   Kohlmann, Markus ^a   Nazaré, Marc ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; GLUTAMIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG IDENTIFICATION; HUMAN; IC 50; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURAL HOMOLOGY; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; GLUTAMIC ACID; HUMANS; MOLECULAR DOCKING SIMULATION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; PYRAZOLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RECEPTORS, PURINERGIC P2Y12; STEREOISOMERISM;

EID: 84867767064     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300771j     Document Type: Article

References (55)

1. Gachet, C. ADP receptors of platelets and their inhibition Thromb. Haemostasis 2001, 86, 222-232
2. Dangelmaier, C.; Jin, J.; Smith, J. B.; Kunapuli, S. P. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway Thromb. Haemostasis 2001, 85, 341-348
3. Cattaneo, M. Advances in antiplatelet therapy: overview of new P2Y12 receptor antagonists in development Eur. Heart J. Suppl. 2008, 10 (Suppl. I) I33-I37
4. Cattaneo, M. ADP receptors: Inhibitory strategies for antiplatelet therapy Drug News Perspect. 2006, 19, 253-259
5. Cattaneo, M. P2Y12 receptor antagonists: A rapidly expanding group of antiplatelet agents Eur. Heart J. 2006, 27, 1010-1012
6. Dogne, J. M.; de Leval, X.; Benoit, P.; Delarge, J.; Masereel, B.; David, J. L. Recent advances in antiplatelet agents Curr. Med. Chem. 2002, 9, 577-589
7. Ingall, A. H.; Dixon, J.; Bailey, A.; Coombs, M. E.; Cox, D.; McInally, J. I.; Hunt, S. F.; Kindon, N. D.; Teobald, B. J.; Willis, P. A.; Humphries, R. G.; Leff, P.; Clegg, J. A.; Smith, J. A.; Tomlinson, W. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy J. Med. Chem. 1999, 42, 213-220
8. Storey, R. F. Biology and pharmacology of the platelet P2Y12 receptor Curr. Pharm. Des. 2006, 12, 1255-1259
9. Nicholas, R. A. Identification of the P2Y(12) receptor: A novel member of the P2Y family of receptors activated by extracellular nucleotides Mol. Pharmacol. 2001, 60, 416-420
10. Dorsam, R. T.; Kunapuli, S. P. Central role of the P2Y12 receptor in platelet activation J. Clin. Invest. 2004, 113, 340-345
11. Judge, H. M.; Buckland, R. J.; Sugidachi, A.; Jakubowski, J. A.; Storey, R. F. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function Thromb. Haemostasis 2010, 103, 1210-1217
12. Andre, P.; Delaney, S. M.; LaRocca, T.; Vincent, D.; DeGuzman, F.; Jurek, M.; Koller, B.; Phillips, D. R.; Conley, P. B. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries J. Clin. Invest. 2003, 112, 398-406
13. Savi, P.; Herbert, J.-M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis Semin. Thromb. Hemostasis 2005, 31, 174-183
14. Hollopeter, G.; Jantzen, H. M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R. B.; Nurden, P.; Nurden, A.; Julius, D.; Conley, P. B. Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 2001, 409, 202-207
15. CAPRIE Steering Committee (CAPRIE). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events Lancet 1996, 348, 1329-1339
16. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (CURE). Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N. Engl. J. Med. 2001, 345, 494-502.
17. Savi, P.; Pereillo, J. M.; Uzabiaga, M. F.; Combalbert, J.; Picard, C.; Maffrand, J. P.; Pascal, M.; Herbert, J.-M. Identification and biological activity of the active metabolite of clopidogrel Thromb. Haemostasis 2000, 84, 891-896
18. Meadows, T. A.; Bhatt, D. L. Clinical aspects of platelet inhibitors and thrombus formation Circ. Res. 2007, 100, 1261-1275
19. Savi, P.; Zachayus, J. L.; Delesque-Touchard, N.; Labouret, C.; Hervé, C.; Uzabiaga, M. F.; Pereillo, J. M.; Culouscou, J. M.; Bono, F.; Ferrara, P.; Herbert, J.-M. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11069-11074
20. Algaier, I.; Jakubowski, J. A.; Asai, F.; Von Kügelgen, I. Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor J. Thromb. Haemostasis 2008, 6, 1908-1914
21. Huber, K.; Hamad, B.; Kirkpatrick, P. Fresh from the pipeline. Ticagrelor Nat. Rev. Drug Discovery 2011, 10, 255-256
22. Gurbel, P. A.; Kereiakes, D. J.; Tantry, U. S. Ticagrelor for the treatment of arterial thrombosis Expert Opin. Pharmacother. 2010, 11, 2251-2259
23. Ueno, M.; Rao, S. V.; Angiolillo, D. J. Elinogrel: Pharmacological principles, preclinical and early phase clinical testing Future Cardiol. 2010, 6, 445-453
24. Oestreich, J. H. Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events Curr. Opin. Invest. Drugs 2010, 11, 340-348
25. Berger, J. S.; Roe, M. T.; Gibson, C. M.; Kilaru, R.; Green, C. L.; Melton, L.; Blankenship, J. D.; Metzger, D. C.; Granger, C. B.; Gretler, D. D; Grines, C. L.; Huber, K.; Zeymer, U.; Buszman, P.; Harrington, R. A.; Armstrong, P. W. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) Am. Heart J. 2009, 158, 998-1004
26. Bryant, J.; Post, J. M.; Alexander, S.; Wang, Y. X.; Kent, L.; Schirm, S.; Tseng, J. L.; Subramanyam, B.; Buckman, B.; Islam, I.; Yuan, S.; Sullivan, M. E.; Snider, M.; Morser, J. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets Thromb. Res. 2008, 122, 523-532
27. Post, J. M.; Alexander, S.; Wang, Y. X.; Vincelette, J.; Vergona, R.; Kent, L.; Bryant, J.; Sullivan, M. E.; Dole, W. P.; Morser, J.; Subramanyam, B. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization Thromb. Res. 2008, 122, 533-540
28. Wang, Y. X.; Vincelette, J.; da Cunha, V.; Martin-McNulty, B.; Mallari, C.; Fitch, R. M.; Alexander, S.; Islam, I.; Buckman, B. O.; Yuan, S.; Post, J. M.; Subramanyam, B.; Vergona, R.; Sullivan, M. E.; Dole, W. P.; Morser, J.; Bryant, J. A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models Thromb. Haemostasis 2007, 97, 847-855
29. Cattaneo, M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function Semin. Thromb. Hemostasis 2009, 35, 158-167
30. Breet, N. J.; van Werkum, J. W.; Bouman, H. J.; Kelder, J. C.; Ruven, H. J. T.; Bal, E. T.; Deneer, V. H.; Harmsze, A. M.; van der Heyden, J. A. S.; Rensing, B. J. W. M.; Suttorp, M. J.; Hackeng, C. M.; ten Berg, J. M. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation J. Am. Med. Assoc. 2010, 303, 754-762
31. Jakubowski, J. A.; Li, Y. G.; Small, D. S.; Payne, C. D.; Tomlin, M. E.; Luo, J.; Winters, K. J. A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: An integrated analysis J. Cardiovasc. Pharmacol. 2010, 56, 29-37
32. Parlow, J. J.; Burney, M. W.; Case, B. L.; Girard, T. J.; Hall, K. A.; Hiebsch, R. R.; Huff, R. M.; Lachance, R. M.; Mischke, D. A.; Rapp, S. R.; Woerndle, R. S.; Ennis, M. D. Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation Bioorg. Med. Chem. Lett. 2009, 19, 4657-4663
33. Parlow, J. J.; Burney, M. W.; Case, B. L.; Girard, T. J.; Hall, K. A.; Harris, P. K.; Hiebsch, R. R.; Huff, R. M.; Lachance, R. M.; Mischke, D. A.; Rapp, S. R.; Woerndle, R. S.; Ennis, M. D. Part II: Piperazinyl-glutamate- pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation Bioorg. Med. Chem. Lett. 2010, 20, 1388-1394
34. Parlow, J. J.; Burney, M. W.; Case, B. L.; Girard, T. J.; Hall, K. A.; Harris, P. K.; Hiebsch, R. R.; Huff, R. M.; Lachance, R. M.; Mischke, D. A.; Rapp, S. R.; Woerndle, R. S.; Ennis, M. D. Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation J. Med. Chem. 2010, 53, 2010-2037
35. Nazare, M.; Zech, G.; Goerlitzer, J.; Just, M.; Weiss, T.; Hessler, G.; Czechtizky, W.; Ruf, S. Pyrazole-carboxamide derivatives as P2Y12 antagonist. WO2009080227, 2009.
36. Nazare, M.; Zech, G.; Just, M.; Weiss, T.; Hessler, G.; Kohlmann, M. Heterocyclic pyrazole-carboxamides as P2Y12 antagonists. WO2009080226, 2009.
37. Caroff, E.; Hilpert, K.; Meyer, E. 2-Phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists. WO2008050301, 2008.
38. Caroff, E.; Hilpert, K.; Meyer, E. Preparation of N-(2-pyridylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists. WO2008044217, 2008.
39. Caroff, E.; Fretz, H.; Hilpert, K.; Houille, O.; Hubler, F.; Meyer, E. Pyrimidine derivatives and their use as P2Y12 receptor antagonists. WO2006114774, 2006.
40. Deflorian, F.; Jacobson, K. A. Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor J. Comput.-Aided. Mol. Des. 2011, 25, 329-338
41. Wheatley, M.; Wootten, D.; Conner, M. T.; Simms, J.; Kendrick, R.; Logan, R. T.; Poyner, D. R.; Barwell, J. Lifting the lid on GPCRs: The role of extracellular loops Br. J. Pharmacol. 2012, 165, 1688-1703
42. Hao, M.; Li, Y.; Wang, Y.; Yan, Y.; Zhang, S.; Li, G.; Yang, L. Combined 3D-QSAR, Molecular Docking, and Molecular Dynamics Study on Piperazinyl- Glutamate-Pyridines/Pyrimidines as Potent P2Y12 Antagonists for Inhibition of Platelet Aggregation J. Chem. Inf. Model. 2011, 51, 2560-2572
43. Takasaki, J.; Kamohara, M.; Saito, T.; Matsumoto, M.; Matsumoto, S.; Ohishi, T.; Soga, T.; Matsushime, H.; Furuichi, K. Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor Mol. Pharmacol. 2001, 60, 432-439
44. Savi, P.; Labouret, C.; Delesque, N.; Guette, F.; Lupker, J.; Herbert, J. M. P2Y(12), a new platelet ADP receptor, target of clopidogrel Biochem. Biophys. Res. Commun. 2001, 283, 379-383
45. Mao, Y.; Zhang, L.; Jin, J.; Ashby, B.; Kunapuli, S. P. Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor Eur. J. Pharmacol. 2010, 644, 10-16
46. Hoffmann, K.; Sixel, U.; Di Pasquale, F.; von Kügelgen, I. Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor Biochem. Pharmacol. 2008, 76, 1201-1213
47. Graff, J.; Klinkhardt, U.; Harder, S. Pharmacodynamic profile of antiplatelet agents: Marked differences between single versus costimulation with platelet activators Thromb. Res. 2004, 113, 295-302
48. Storey, R. F.; Newby, L. J.; Heptinstall, S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood Platelets 2001, 12, 443-447
49. Sugidachi, A.; Asai, F.; Yoneda, K.; Iwamura, R.; Ogawa, T.; Otsuguro, K.; Koike, H. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747 Br. J. Pharmacol. 2001, 132, 47-54
50. Huang, J.; Driscoll, E. M.; Gonzales, M. L.; Park, A. M.; Lucchesi, B. R. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model J. Pharmacol. Exp. Ther. 2000, 295, 492-499
51. Soloviev, M. V.; Okazaki, Y.; Harasaki, H. Whole blood platelet aggregation in humans and animals: A comparative study J. Surg. Res. 1999, 82, 180-187
52. Klabunde, T.; Giegerich, C.; Evers, A. MARS: Computing three-dimensional alignments for multiple ligands using pairwise similarities J. Chem. Inf. Model. 2012, 52, 2022-2030
53. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel procedure for modeling ligand/receptor induced fit effects J. Med. Chem. 2006, 49, 534-553
54. Rush, T. S., III; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction J. Med. Chem. 2005, 48, 1489-1495
55. SYBYL Molecular Modelling Package, Version 8.0; Tripos: St. Louis, MO, 2009.